Koji Kato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Koji Kato has a total of 264 co-authors. Here are the top co-authors by number of shared publications:
- Nao Yoshida
Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital, Nagoya, Japan
7 shared publications Kimikazu Matsumoto
Children's Cancer Center National Center for Child Health and Development Tokyo Japan
6 shared publications- Yoshiko Atsuta
Japanese Data Center for Hematopoietic Cell Transplantation Nagakute Aichi Japan
6 shared publications Ken Tabuchi
Japanese Data Center for Hematopoietic Cell Transplantation Nagakute Aichi Japan
5 shared publicationsNao Yoshida
Department of Hematology and Oncology Children's Medical Center Japanese Red Cross Nagoya First Hospital Nagoya Japan
5 shared publications- Naoyuki Uchida
Department of Hematology Toranomon Hospital Tokyo Japan
4 shared publications
Latest Publications
- 28 October 2026
- Published by Wiley in British Journal of Haematology
Second allogeneic haematopoietic stem cell transplantation for non‐malignant diseases
Summary: We retrospectively analysed clinical outcomes of 152 patients with non‐malignant diseases (NMDs) who underwent a second allogeneic haematopoietic stem cell transplantation (HSCT), using a composite end‐point, graft‐versus‐host disease (GVHD)‐free, relapse (i.e. graft failure)‐free and subsequent transplant‐free survival (GRSFS), to assess major failure events. The 5‐year overall survival (OS) and GRSFS rates were 67.0% and 52.1%, respectively. Graft failure (GF) was the most frequent GRSFS failure event, occurring in 24.5% of patients. In multivariate analysis, use of a human leucocyte antigen 0–1 antigen mismatch unrelated bone marrow (BM)/peripheral blood stem cell (PBSC) donor, unrelated cord blood (CB) donor and no donor change were associated with lower incidence of engraftment ( p < 0.01). In addition to conditioning and human leucocyte antigen (HLA) compatibility in second HSCT, disease group was identified as an independent risk factor for GRSFS. Specifically, patients with haemophagocytic lymphohistiocytosis had the poorest outcome ( p = 0.04), while those with inherited metabolic diseases (IMDs) tended towards more favourable outcome ( p = 0.06). Among the 51 deaths, 44 (86.6%) were attributed to causes other than the original disease, with variation across disease groups. GRSFS may be a useful metric to quantify the clinical impact of major failure events and to inform strategies for second HSCT in NMDs.
- 28 October 2026
- Published by Wiley in British Journal of Haematology
Second allogeneic haematopoietic stem cell transplantation for non‐malignant diseases
Summary: We retrospectively analysed clinical outcomes of 152 patients with non‐malignant diseases (NMDs) who underwent a second allogeneic haematopoietic stem cell transplantation (HSCT), using a composite end‐point, graft‐versus‐host disease (GVHD)‐free, relapse (i.e. graft failure)‐free and subsequent transplant‐free survival (GRSFS), to assess major failure events. The 5‐year overall survival (OS) and GRSFS rates were 67.0% and 52.1%, respectively. Graft failure (GF) was the most frequent GRSFS failure event, occurring in 24.5% of patients. In multivariate analysis, use of a human leucocyte antigen 0–1 antigen mismatch unrelated bone marrow (BM)/peripheral blood stem cell (PBSC) donor, unrelated cord blood (CB) donor and no donor change were associated with lower incidence of engraftment ( p < 0.01). In addition to conditioning and human leucocyte antigen (HLA) compatibility in second HSCT, disease group was identified as an independent risk factor for GRSFS. Specifically, patients with haemophagocytic lymphohistiocytosis had the poorest outcome ( p = 0.04), while those with inherited metabolic diseases (IMDs) tended towards more favourable outcome ( p = 0.06). Among the 51 deaths, 44 (86.6%) were attributed to causes other than the original disease, with variation across disease groups. GRSFS may be a useful metric to quantify the clinical impact of major failure events and to inform strategies for second HSCT in NMDs.
- 26 July 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1797-1806
Donor age as a dual‐risk factor for donor safety and recipient survival in allogeneic haematopoietic stem cell transplantation
Summary: Donor selection in allogeneic haematopoietic stem cell transplantation (allo‐HSCT) requires balancing donor safety and recipient survival. We aimed to identify dual—association donor factors (DADFs)—donor characteristics associated with both increased serious adverse events (SAEs) and inferior patient survival—using umbilical cord blood (UCB) as a donor‐safety benchmark. This nationwide retrospective cohort study analysed Japanese registry data (2013–2022) including 22 892 donors and 29 559 recipients. Logistic regression identified donor SAE risk factors, while patient outcomes were evaluated using inverse probability of treatment weighting (IPTW)‐adjusted Cox models with UCB as reference. Propensity score matching (PSM) compared UCB with older donor haploidentical transplantation using post‐transplant cyclophosphamide (OD‐PTCy‐Haplo). Among donors, 93 (0.41%) experienced an SAE. Older donor age and female sex were independent risk factors for SAE. In IPTW‐adjusted analyses, allo‐HSCT from older haploidentical donors was associated with inferior overall survival (OS) and relapse‐free survival (RFS) compared with UCB. In PSM analyses of elderly high‐risk recipients, OD‐PTCy‐Haplo resulted in significantly worse OS and RFS than UCB. Older donor age emerged as a donor characteristic associated with increased donor SAE risk and inferior patient survival, particularly in haploidentical transplantation. UCB may offer a more favourable balance between donor safety and patient outcomes in selected high‐risk settings.
- 26 July 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1797-1806
Donor age as a dual‐risk factor for donor safety and recipient survival in allogeneic haematopoietic stem cell transplantation
Summary: Donor selection in allogeneic haematopoietic stem cell transplantation (allo‐HSCT) requires balancing donor safety and recipient survival. We aimed to identify dual—association donor factors (DADFs)—donor characteristics associated with both increased serious adverse events (SAEs) and inferior patient survival—using umbilical cord blood (UCB) as a donor‐safety benchmark. This nationwide retrospective cohort study analysed Japanese registry data (2013–2022) including 22 892 donors and 29 559 recipients. Logistic regression identified donor SAE risk factors, while patient outcomes were evaluated using inverse probability of treatment weighting (IPTW)‐adjusted Cox models with UCB as reference. Propensity score matching (PSM) compared UCB with older donor haploidentical transplantation using post‐transplant cyclophosphamide (OD‐PTCy‐Haplo). Among donors, 93 (0.41%) experienced an SAE. Older donor age and female sex were independent risk factors for SAE. In IPTW‐adjusted analyses, allo‐HSCT from older haploidentical donors was associated with inferior overall survival (OS) and relapse‐free survival (RFS) compared with UCB. In PSM analyses of elderly high‐risk recipients, OD‐PTCy‐Haplo resulted in significantly worse OS and RFS than UCB. Older donor age emerged as a donor characteristic associated with increased donor SAE risk and inferior patient survival, particularly in haploidentical transplantation. UCB may offer a more favourable balance between donor safety and patient outcomes in selected high‐risk settings.
- 18 February 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (4) , 1369-1379
Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders
Summary: In allogeneic haematopoietic stem cell transplantation (allo‐HSCT) for genetic disorders (GDs), predicting outcomes using the currently used myeloablative/reduced‐intensity conditioning classification is challenging. We examined the utility of the transplant conditioning intensity (TCI) score in allo‐HSCT for GDs. We retrospectively analysed 1077 patients who underwent first allo‐HSCT for GDs between 1987 and 2018. While no significant difference was observed in 3‐year non‐relapse mortality (NRM) between the myeloablative and reduced‐intensity conditioning group, 3‐year NRM in the TCI score ≥4.0 (TCI‐high) group (17.3%) was higher than that in the TCI score 0.5–3.5 (TCI‐low/intermediate) group (11.6%, p = 0.013). Multivariate analysis identified a high TCI score as a significant factor for NRM (HR 1.56, p = 0.011). Infection‐related mortalities were more prevalent in the TCI‐high group (7.9%) compared with the TCI‐low/intermediate group (3.2%). In contrast, patients in the TCI‐high group achieved a significantly higher rate of complete donor chimerism (71.7%) than those in the TCI‐low/intermediate group (62.2%, p = 0.022). TCI score is a valuable tool for predicting outcomes after allo‐HSCT for GDs as well as for guiding the selection of conditioning regimens tailored to the unique characteristics of GDs.
- 18 February 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (4) , 1369-1379
Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders
Summary: In allogeneic haematopoietic stem cell transplantation (allo‐HSCT) for genetic disorders (GDs), predicting outcomes using the currently used myeloablative/reduced‐intensity conditioning classification is challenging. We examined the utility of the transplant conditioning intensity (TCI) score in allo‐HSCT for GDs. We retrospectively analysed 1077 patients who underwent first allo‐HSCT for GDs between 1987 and 2018. While no significant difference was observed in 3‐year non‐relapse mortality (NRM) between the myeloablative and reduced‐intensity conditioning group, 3‐year NRM in the TCI score ≥4.0 (TCI‐high) group (17.3%) was higher than that in the TCI score 0.5–3.5 (TCI‐low/intermediate) group (11.6%, p = 0.013). Multivariate analysis identified a high TCI score as a significant factor for NRM (HR 1.56, p = 0.011). Infection‐related mortalities were more prevalent in the TCI‐high group (7.9%) compared with the TCI‐low/intermediate group (3.2%). In contrast, patients in the TCI‐high group achieved a significantly higher rate of complete donor chimerism (71.7%) than those in the TCI‐low/intermediate group (62.2%, p = 0.022). TCI score is a valuable tool for predicting outcomes after allo‐HSCT for GDs as well as for guiding the selection of conditioning regimens tailored to the unique characteristics of GDs.
- Open Access
- 17 October 2025
- Published by Springer Nature in Research Square
Donor type/graft source selection strategies based on disease status for paediatric acute myeloid leukemia transplantation
In the absence of a human leukocyte antigen-matched sibling donor for paediatric patients with acute myeloid leukemia (AML) who underwent the first allogeneic hematopoietic cell transplantation (allo-HCT), the optimal donor type/graft source remain undetermined among donor types—haploidentical related donor (HRD) and matched unrelated donor (MUD)—as well as graft source—umbilical cord blood (UCB). This study aimed to determine the optimal donor type/graft source. The Japanese database on 441 recipients (median age, 6.0 years, range [0.0–15.0]) for HRD (n = 71), MUD (n = 111), and UCB (n = 259) was analyzed retrospectively. Regarding recipients in remission [complete remission (CR) 1 or CR2 at allo-HCT, n = 271], the rate of a composite endpoint consisting of extensive chronic graft-versus-host disease (cGVHD)- and leukemia-free survival (LFS)—extensive cGVHD-LFS—was not statistically significant among UCB, MUD, and HRD recipients. Regarding recipients not in remission (n =170), extensive cGVHD-LFS was significantly higher for MUD recipients than for UCB ( p = 0.007) and HRD ( p = 0.015) recipients. HRD, MUD, and UCB were optimal for recipients in remission, while MUD was optimal for recipients not in remission. Namely, the donor type/graft source needs to be selected based on disease status at HCT.
- 17 October 2025
- Published by Springer Nature in Research Square
Open AccessDonor type/graft source selection strategies based on disease status for paediatric acute myeloid leukemia transplantation
In the absence of a human leukocyte antigen-matched sibling donor for paediatric patients with acute myeloid leukemia (AML) who underwent the first allogeneic hematopoietic cell transplantation (allo-HCT), the optimal donor type/graft source remain undetermined among donor types—haploidentical related donor (HRD) and matched unrelated donor (MUD)—as well as graft source—umbilical cord blood (UCB). This study aimed to determine the optimal donor type/graft source. The Japanese database on 441 recipients (median age, 6.0 years, range [0.0–15.0]) for HRD (n = 71), MUD (n = 111), and UCB (n = 259) was analyzed retrospectively. Regarding recipients in remission [complete remission (CR) 1 or CR2 at allo-HCT, n = 271], the rate of a composite endpoint consisting of extensive chronic graft-versus-host disease (cGVHD)- and leukemia-free survival (LFS)—extensive cGVHD-LFS—was not statistically significant among UCB, MUD, and HRD recipients. Regarding recipients not in remission (n =170), extensive cGVHD-LFS was significantly higher for MUD recipients than for UCB ( p = 0.007) and HRD ( p = 0.015) recipients. HRD, MUD, and UCB were optimal for recipients in remission, while MUD was optimal for recipients not in remission. Namely, the donor type/graft source needs to be selected based on disease status at HCT.
- Open Access
- 23 August 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (11) , 1102.e1-1102.e12
A Retrospective Study of Pediatric Patients With Low- or Intermediate-Risk Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation for the AML-05 Study Conducted by the Japanese Pediatric Leukemia/Lymphoma Study Group
- 23 August 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (11) , 1102.e1-1102.e12
Open AccessA Retrospective Study of Pediatric Patients With Low- or Intermediate-Risk Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation for the AML-05 Study Conducted by the Japanese Pediatric Leukemia/Lymphoma Study Group
- Open Access
- 7 February 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (4) , 444.e1-444.e11
Machine Learning Prediction Model for Neutrophil Recovery after Unrelated Cord Blood Transplantation
- 7 February 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (4) , 444.e1-444.e11
Open AccessMachine Learning Prediction Model for Neutrophil Recovery after Unrelated Cord Blood Transplantation
- 14 June 2022
- Published by Springer Nature in International Journal of Hematology
- Vol. 116 (4) , 1-9
Prognostic value of pre-transplantation total metabolic tumor volume on 18fluoro-2-deoxy-d-glucose positron emission tomography–computed tomography in relapsed and refractory aggressive lymphoma
Relapsed and refractory aggressive lymphoma have a poor prognosis. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is effective in chemosensitive patients. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is among the few options for non-chemosensitive patients. 18Fluoro-2-deoxy-d-glucose positron emission tomography–computed tomography (18FDG-PET/CT) is the standard tool for evaluating response to chemotherapy and residual tumor volume. However, accurate assessment of residual tumor volume is not currently being achieved in clinical practice, and its value in prognostic and therapeutic stratification remains unclear. To answer this question, we investigated the efficacy of quantitative indicators, including total metabolic tumor volume (TMTV), in predicting prognosis after auto-HSCT and allo-HSCT. We retrospectively analyzed 39 patients who received auto-HSCT and 28 who received allo-HSCT. In the auto-HSCT group, patients with a higher TMTV had a poor prognosis due to greater risk of relapse. In the allo-HSCT group, patients with a higher TMTV had a lower progression-free survival rate and a significantly higher relapse rate. Neither Deauville score nor other clinical parameters were associated with prognosis in either group. Therefore, pre-transplant TMTV on PET is effective for prognostic prediction and therapeutic decision-making for relapsed or refractory aggressive lymphoma.
- 14 June 2022
- Published by Springer Nature in International Journal of Hematology
- Vol. 116 (4) , 1-9
Prognostic value of pre-transplantation total metabolic tumor volume on 18fluoro-2-deoxy-d-glucose positron emission tomography–computed tomography in relapsed and refractory aggressive lymphoma
Relapsed and refractory aggressive lymphoma have a poor prognosis. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is effective in chemosensitive patients. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is among the few options for non-chemosensitive patients. 18Fluoro-2-deoxy-d-glucose positron emission tomography–computed tomography (18FDG-PET/CT) is the standard tool for evaluating response to chemotherapy and residual tumor volume. However, accurate assessment of residual tumor volume is not currently being achieved in clinical practice, and its value in prognostic and therapeutic stratification remains unclear. To answer this question, we investigated the efficacy of quantitative indicators, including total metabolic tumor volume (TMTV), in predicting prognosis after auto-HSCT and allo-HSCT. We retrospectively analyzed 39 patients who received auto-HSCT and 28 who received allo-HSCT. In the auto-HSCT group, patients with a higher TMTV had a poor prognosis due to greater risk of relapse. In the allo-HSCT group, patients with a higher TMTV had a lower progression-free survival rate and a significantly higher relapse rate. Neither Deauville score nor other clinical parameters were associated with prognosis in either group. Therefore, pre-transplant TMTV on PET is effective for prognostic prediction and therapeutic decision-making for relapsed or refractory aggressive lymphoma.
- 18 October 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 26 (1) , e14125
Stem cell transplantation for pediatric patients with adrenoleukodystrophy: A nationwide retrospective analysis in Japan
Background: Adrenoleukodystrophy (ALD) is an X‐linked recessive disorder and 30–40% of patients develop progressive cerebral neurodegeneration. For symptomatic ALD patients, allogeneic stem cell transplantation (SCT) is considered the standard treatment modality to stabilize or prevent the progression of neurological symptoms.Methods: We retrospectively analyzed the transplant outcomes of 99 pediatric patients with cerebral ALD in Japan. The conditioning regimens included Regimen A: fludarabine/melphalan/low‐dose total body irradiation (TBI) with brain sparing (n = 39), Regimen B; busulfan/cyclophosphamide ± others (n = 23), Regimen C: melphalan/total lymphoid irradiation/thoracoabdominal irradiation ± anti‐T lymphocyte globulin ± fludarabine (n = 27), and Regimen D: others (n = 10).Results: The 5‐year overall survival (OS) and event‐free survival (EFS) of all patients were 90.0% and 72.9%, respectively. The 5‐year OS was 100.0% for Regimen A, 91.1% for Regimen B, 84.4% for Regimen C, and 67.5% for Regimen D (p = 0.028). The 5‐year EFS was 78.3% for Regimen A, 78.0% for Regimen B, 70.4% for Regimen C, and 48.0% for Regimen D (p = 0.304). The OS marginally improved after 2007 compared with before 2006 (95.3% vs. 85.2%, p = 0.066), due to the improvement of cord blood transplantation (CBT) outcomes after 2007 compared with before 2006 (96.6% vs. 68.4%, p = 0.005). On magnetic resonance imaging of the brain, a reduced Loes score after SCT was only observed in one of the 15 bone marrow transplantation (BMT) patients, but in 5 of the 15 CBT patients (p = 0.173).Conclusions: Our study revealed that a reduced conditioning regimen with fludarabine/melphalan/low‐dose TBI provides better outcomes, and the results of CBT significantly improved after 2007.
- 18 October 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 26 (1) , e14125
Stem cell transplantation for pediatric patients with adrenoleukodystrophy: A nationwide retrospective analysis in Japan
Background: Adrenoleukodystrophy (ALD) is an X‐linked recessive disorder and 30–40% of patients develop progressive cerebral neurodegeneration. For symptomatic ALD patients, allogeneic stem cell transplantation (SCT) is considered the standard treatment modality to stabilize or prevent the progression of neurological symptoms.Methods: We retrospectively analyzed the transplant outcomes of 99 pediatric patients with cerebral ALD in Japan. The conditioning regimens included Regimen A: fludarabine/melphalan/low‐dose total body irradiation (TBI) with brain sparing (n = 39), Regimen B; busulfan/cyclophosphamide ± others (n = 23), Regimen C: melphalan/total lymphoid irradiation/thoracoabdominal irradiation ± anti‐T lymphocyte globulin ± fludarabine (n = 27), and Regimen D: others (n = 10).Results: The 5‐year overall survival (OS) and event‐free survival (EFS) of all patients were 90.0% and 72.9%, respectively. The 5‐year OS was 100.0% for Regimen A, 91.1% for Regimen B, 84.4% for Regimen C, and 67.5% for Regimen D (p = 0.028). The 5‐year EFS was 78.3% for Regimen A, 78.0% for Regimen B, 70.4% for Regimen C, and 48.0% for Regimen D (p = 0.304). The OS marginally improved after 2007 compared with before 2006 (95.3% vs. 85.2%, p = 0.066), due to the improvement of cord blood transplantation (CBT) outcomes after 2007 compared with before 2006 (96.6% vs. 68.4%, p = 0.005). On magnetic resonance imaging of the brain, a reduced Loes score after SCT was only observed in one of the 15 bone marrow transplantation (BMT) patients, but in 5 of the 15 CBT patients (p = 0.173).Conclusions: Our study revealed that a reduced conditioning regimen with fludarabine/melphalan/low‐dose TBI provides better outcomes, and the results of CBT significantly improved after 2007.